337th Edition – January 15, 2019

BioHealth Innovation, Inc. (BHI) announced today that John P. Sullivan has joined BHI as a new Entrepreneur-in-Residence (EIR) for the National Institutes of Health (NIH), working with Ethel Rubin, PhD, ventures team head, to provide product, corporate and private investment strategy for NIH portfolio companies.

“We are pleased to have Mr. Sullivan join the team of EIRs serving NIH,” said Richard Bendis, BHI President and CEO. “His expertise in building, operating and acquiring health technology businesses will certainly be an asset as he works to provide the institution with industry insights and commercialization perspectives.”

Established with NIH in 2012, the EIR program is designed to connect NIH-funded start-ups with experienced industry experts who can help them maneuver through multi-disciplinary technical challenges and the business and regulatory environment to deploy new healthcare and biomedical technologies.

Read More

Montgomery beat out Boston and the Philadelphia areas to win the project.

Read More

A sign of the BioHealth Capital Region’s industry growth is the increase in hiring taking place throughout the region.   More than 1800 job opportunities are listed on BioHealth Innovation’s website (www.BioHealthInnovation.org/Jobs).  Many with relatively young companies expanding their regulatory, manufacturing and R&D teams.  To post positions, Email:  BHI@BioHealthInnovation.org.

Read More

GlaxoSmithKline – Advancing the science of vaccines and improving lives around the world.

Read More

Is the pain stabbing or burning? On a scale from 1 to 10, is it a 6 or an 8?

Over and over, 17-year-old Sarah Taylor struggled to make doctors understand her sometimes debilitating levels of pain, first from joint-damaging childhood arthritis and then from fibromyalgia.

Read More

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus’ U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually. In addition, Autolus has established a temporary U.S. headquarters in Rockville until the new facility is ready for occupancy, which is currently expected to occur in 2021.

Read More

Join us for the January 23, 2019 for PATHFINDER INNOVATION PROGRAM

Learn more about:

• Overview and Reporting Requirements for Type of Entity
• Impact of Accounting Methods 
• Start-up Company Issues
• International Investment
• Tax Law Changes
• State Tax Concerns
• Tax Planning

Schedule

12:00 p.m – Networking Lunch

12:30 – 1:30 p.m. – Discussion with Q&A*  – Tom Christiana, Partner – Aronson, LLC

1:30 – 4:00 p.m. – One-on-one Meetings**

RSVP by noon, January 22, at BHI@BioHealthInnovation.org

No charge to attend but pre-registration is required.

*Attend in person (1 Church St, Rockville) or by videoconference

**Attendance at discussion is required to participate in 1:1

Download Flyer »

Read More

HOLD THE DATE – January 29, 2019  8 am. – 12:30 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!) 

8-8:30 Networking and Registration

8:30 – 10:00 a.m. – Program Overviews*

10:00 – 12:30 p.m. – 1:1 Meetings with Program Managers**

Agencies represented include:   NSF, NIH NIA, NIH NCATS, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings.  However, to do so, you must attend the overview session in person.PRE-REGISTRATION IS REQUIRED:  RSVP by noon 1/27:  BHI@BioHealthInnovation.org

Read More

Please join me in celebrating two exciting leadership changes at JHTV. Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at JHTV since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

Read More

MOVE over Caltech, Georgia Tech, and MIT – the University of Oxford has been named the best university in the world for computer science degrees for 2019. The ranking compares the top computer science programs in the world. ETH Zurich ranked number 2 on the list, followed by Stanford University (No. 3), the University of Cambridge (No. 4), and Massachusetts Institute of Technology (No. 5).

Read More

The Food and Drug Administration plans to create a new office to improve the review of new medicines — one that will develop a standardized approach to using personalized medicine, digital data, and patients’ own reports, according to Commissioner Scott Gottlieb.

Read More

2018 was a record year for biopharma initial public offerings (IPOs), with an all-time high of $6.3 billion raised by 58 U.S. companies as of December 17, according to Renaissance Capital, compared with 36 companies garnering some $4 billion in 2017.

Read More

Pharmaceutical companies are starting to see the retail supply chain as more than just a way to get drugs from point A to point B. It can be an opportunity to ensure better products and services and create a competitive advantage with consumers – but only if data is connected and well managed.

Read More

A pair of Baltimore-based digital health startups were among the award winners at the conclusion of the Accenture HealthTech Innovation Challenge this week.

Read More

Precision medicine is using knowledge about a person’s genetic code to tailor treatments to that individual for the most optimal outcome. Think of sequencing tumors and then determining a treatment regimen based on biomarkers or genetic variants.

Read More

For months, it had been clear that 2018 would be a banner year for pharmaceutical innovation. The question was, by how much would it shatter the previous (1996) record of 50 approvals (excluding diagnostics and imaging agents)? We now know. It exceeded it by over 20 percent. Last year, U.S. regulators approved a total of 61 drugs – 59 by FDA’s Center for Drug Evaluation and Research (CDER), plus two recombinant therapies (Andexxa and Jivi) by its Center for Biologics Evaluation and Research (CBER).

Read More

Indicators of Innovation, a report issued today by the New Jersey Business & Industry Association, shows New Jersey at a challenging crossroads in its efforts to reclaim itself as the “Innovation State.”

Read More

Brianna Wronko has an engineering degree from an Ivy League school and is the CEO of a health-care diagnostics company. Until this week, she never thought she’d be stuck holding business meetings in a San Francisco hotel bathroom.

Read More